当前位置:首页 > 报告详情

JPM 2023 Sutro.pdf

上传人: 2*** 编号:142988 2023-09-30 25页 2.72MB

1、NON-CONFIDENTIALNON-CONFIDENTIAL40thAnnual J.P.MorganHealthcare ConferenceJanuary 2022Sutro Biopharma NASDAQ:STRONON-CONFIDENTIALForward Looking StatementsThis presentation and the accompanying oral presentation contain“forward-looking”statements that are based on our managements beliefs and assumpt

2、ions and on information currently available to management.Forward-looking statements include all statements other than statements of historical fact contained in this presentation,including information concerning our future financial performance,business plans and objectives,current and future clini

3、cal activities,timing and success of our ongoing and planned clinical trials and related data,updates and results of our clinical trials and related data,timing and success of our planned development activities,our ability to obtain and maintain regulatory approval,the potential therapeutic benefits

4、 and economic value of our product candidates,potential growth opportunities,financing plans,potential future milestone and royalty payments,competitive position,industry environment and potential market opportunities for the Companys product candidates.Forward-looking statements are subject to know

5、n and unknown risks,uncertainties,assumptions and other factors,including risks and uncertainties related to our cash forecasts,our and our collaborators ability to advance our product candidates,the receipt and timing of potential regulatory submissions,designations,approvals and commercialization

6、of product candidates,the timing and results of preclinical and clinical trials,and the expected impact of the COVID-19 pandemic on our operations.It is not possible for our management to predict all risks,nor can we assess the impact of all factors on our business or the extent to which any factor,

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Sutro Biopharma公司在2022年J.P. Morgan医疗保健会议上关于其药物研发平台的进展和产品管线。主要内容包括: 1. Sutro的药物研发平台能够设计出最佳药物分子,包括抗体药物偶联物(ADC)、双特异性抗体和细胞因子衍生物。 2. Sutro的ADC药物STRO-002针对卵巢癌和子宫内膜癌,已在中国与Tasly签订合作协议,并在美国进行临床试验。STRO-002的初步数据显示,5.2mg/kg起始剂量组的客观缓解率(ORR)为47.1%,而所有患者中ORR为33.3%。 3. Sutro的ADC药物STRO-001针对B细胞恶性肿瘤,正在进行临床试验。在非霍奇金淋巴瘤(NHL)患者中,STRO-001的初步数据显示,0.075mg/kg和0.65mg/kg剂量组的2名患者达到部分缓解(PR)。 4. Sutro的财务状况良好,截至2021年9月30日,现金、现金等价物和市场证券总额约为1.6亿美元。
斯图罗生物制药公司2022年有哪些重要的发展计划? 斯图罗生物制药公司的主要产品STRO-002在卵巢癌治疗方面有哪些优势? 斯图罗生物制药公司的财务状况如何,有哪些资金来源?
客服
商务合作
小程序
服务号
折叠